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Jeanette M. Ricci,1 Victoria Flores,2 Isabela Kuroyama,3 Arash Asher,4 and Heather P. Tarleton1,*
Abstract
Fatigue, stress, and depression contribute to poor health-related quality of life (HRQoL) among cancer survivors.
This study examined the effects of combined aerobic and resistance training (CART) on HRQoL and biomarkers of
stress. Cancer survivors (n = 76, 91% female, 39% breast cancer, 32% gynecologic cancer) were enrolled in CART
for three 60-min sessions, weekly, for 26 weeks. Participants completed the National Institutes of Health’s Patient
Reported Outcomes Measurement Information System (NIH PROMIS) fatigue assessment and the SF-36. Cortisol and c-reactive protein (CRP) were assessed using volunteered blood specimens. Baseline fatigue scores
were worse for participants completing treatment within the last year, compared to long-term survivors
[F = (2, 59) = 3.470, p = 0.038]. After 26 weeks, fatigue scores improved by a noteworthy two points [M = 52.72,
standard deviation, SD = 10.10 vs. M = 50.67, SD = 10.14; t(48) = 1.7145, p = 0.092]. Pre- to postintervention improvements in bodily pain [M = 50.54, SD = 9.51 vs. M = 48.20, SD = 10.07; t(33) = 2.913, p = 0.006] and limitations
in social functioning [M = 50.60, SD = 9.17 vs. M = 47.75, SD = 11.66; t(33) = 2.206, p = 0.034], as well as a mean decrease of 1.64 – 10.11 mg/L in CRP levels [t(107) = 1.261, p = 5.965], were observed. Participants within 1 year of
treatment completion experienced greater improvements in post CRP levels compared to those who had treatment 1–4 years ( p = 0.030) and 5 or more years ago ( p = 0.023). Physical functioning, fatigue, fear/anxiety, social
role satisfaction, and CRP levels improved following participation in this exercise intervention. Oncologists should
consider recommending CART as soon as medically feasible following the cessation of cancer treatment.
Keywords: aerobic and resistance training; cancer survivors; c-reactive protein; cortisol; fatigue; health-related
quality of life

reportedly meeting the criteria for post-traumatic
stress disorder.2 Survivors with untreated fatigue and
stress are less likely to adhere to recommended cancer
surveillance and are less likely to engage in healthpromoting activities.3
Physical activity is linked to increased functional capacity, improved mood, increased immune function,
decreased fatigue, improved health perceptions, and

Background
Medical advances will lead to a larger population of
aging adults who can be classiﬁed as cancer survivors
and who may face challenges such as worsening healthrelated quality of life (HRQoL).1 After treatment, survivors experience depression, fatigue and poor motivation
to engage physically in daily activities and may develop
anxiety and fear with as many as 19% of survivors
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improved HRQoL.4,5 From a psychosocial perspective,
participating in physical activity provides a positive feedback loop as the cancer survivor sees his/her body respond
and engage successfully in exercise.6 From a biological
perspective, exercise has been suggested to reduce stress
and chronic inﬂammation.7 Stress and chronic inﬂammation are indicated by high levels of cortisol and c-reactive
protein (CRP), respectively. Abnormally high cortisol levels can also disrupt the hypothalamic-pituitary-adrenal
axis and contribute to an increase in CRP.8 High levels
of CRP are associated with poor HRQoL, impaired physical function, and fatigue in cancer survivors.9,10
The Improving Physical Activity After Cancer
Treatment Study
Previously published studies of exercise interventions
in cancer survivors focused on one exercise modality,
often in a short (e.g., 12-week) intervention period.4
This study’s exercise prescription uses a combined aerobic and resistance training (CART) protocol with the
addition of core strengthening and ﬂexibility over a 26week intervention period.
Data collected and pooled from two cohorts of cancer survivors that participated in the 26-week exercise
program were used to determine whether there is a
dose–response relationship between participation in
exercise training and changes in self-reported
HRQoL. The study also aimed to strengthen the
existing body of literature by adding pre- and postintervention measurement of cortisol and CRP to assess
whether there is a dose–response relationship between
participation in exercise training and change in physiological stress and inﬂammation, respectively.
Materials and Methods
Study population
The Improving Physical Activity After Cancer Treatment (IMPAACT) Study was designed as a prospective
study of the effect of participation in a 26-week exercise
training program on the health of cancer survivors. The
study was approved by the Loyola Marymount University Institutional Review Board (LMU IRB 2014 SP
27 and LMU IRB 2015 SP 23) and the California Health
and Human Services Agency Institutional Review
Board (Protocol ID 14-02-1507) in accordance with
the Helsinki Declaration of 1975, as revised in 1983,
and the Declaration of the World Medical Association.
Two cohorts of cancer survivors were recruited
(Cohort #1, n = 33 and Cohort #2, n = 43) at two timepoints by convenience sampling using survey distribu-
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tion in Los Angeles County, cancer survivor support
group referral, and physician referral. Written informed
consent was ascertained before study enrollment. Individuals had to meet the following criteria to be eligible for
participation: primary diagnosis of cancer, treatment completed at any point before the study, and physical ability to
partake in moderate-intensity weight-bearing exercise.
Participants were excluded from the study if they
presented with any of the following conditions: pregnancy, stroke, or heart attack within past 6 months
and lymphedema. Participants were asked to inform
their physicians of their planned participation and to
review the exercise and assessment protocols with
their physicians before the intervention.
Assessments
Demographics, NIH PROMIS, and SF-36. At recruitment, participants self-reported demographics, comorbidities, health behaviors, and perception of physical
activity level. Participants’ height and weight were collected by trained researchers to compute body mass
index (BMI), in addition to completing waist circumference measurements. Participants’ HRQoL was
assessed using the fatigue domain of the National Institutes of Health’s Patient Reported Outcomes Measurement Information System, version 1.0 (NIH PROMIS)
and the 36-item short-form survey, version 2.0 (SF-36).
Participants completed the NIH PROMIS fatigue assessment, a subcomponent of the physical function domain with applicability in diverse samples of cancer
patients.11 The NIH PROMIS fatigue assessment has
been validated against the Fatigue Symptom Inventory and the Functional Assessment of Chronic Illness
Therapy-Fatigue to measure fatigue severity and disruptiveness in cancer patients and cancer survivors.12,13
A three-to-ﬁve point change in fatigue T-score has
been estimated as clinically meaningful for cancer patients and across cancer type.12,14 Administration of
the NIH PROMIS fatigue survey included computerized adaptive testing (CAT) for Cohort #1 and the
eight item short-form paper (version 1.0, Fatigue 8a)
for Cohort #2. The short form has been shown to be a reliable and precise alternative for CAT regarding psychometric analysis of fatigue, with no differential effect on
the validity of scores across mode of assessment.15
The psychometric properties of the SF measures on
various cancer patients and survivors have been
assessed and shown to have good internal consistency
and validity.16 Clinically meaningful and statistically
signiﬁcant postintervention differences following an
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exercise program have been reported as a change by 4–
15 T-score points.17,18
Biomarkers. Blood specimens were collected by a licensed phlebotomist between 7 and 9am following an
overnight fast at baseline, midpoint, and postintervention to measure serum concentrations of cortisol and
CRP. Serum was isolated by trained laboratory technicians at the LMU Biomedical Sciences Laboratory and
stored at 80C. Cortisol (Abcam 108665; intra-assay
£9.0% coefﬁcient of variation [CV], interassay £9.0%
CV) and CRP (Millipore HNDG2MAG-36; intraassay <10% CV, interassay <15% CV) were analyzed
from isolated serum at the Norris Comprehensive Cancer Center at the University of Southern California. All
blood specimens were deidentiﬁed and coded using a
nonpersonal, randomly assigned study identiﬁcation
number.
Intervention
All assessments and exercise sessions were supervised
by a registered clinical exercise physiologist and by an
American College of Sports Medicine (ACSM) certiﬁed
health ﬁtness specialist. Participants completed 60-min
sessions, three times a week for 26 weeks, that included
15 min of aerobic walking/running at 35–85% heart rate
reserve, 30 min of whole body circuit training, and
15 min of ﬂexibility and core training as prescribed in
accordance with the Guidelines for Exercise for Cancer
Survivors from the ACSM.19 Each participant wore a
Polar heart rate monitor (Polar Electro, Lake Success,
NY) for assessments and exercise sessions, and all assessment and training staff were trained in First Aid
and certiﬁed in cardio-pulmonary resuscitation.
Data analysis
Data from both cohorts were pooled given the high degree of similarity in the source population for participant
recruitment and in data collection and intervention protocols. Analysis of Cohort #1 is based on 33 enrolled participants with 21 (64%) completing the intervention.
Analysis of Cohort #2 is based on 43 enrolled participants with 35 (81%) completing the intervention.
Cohort #1 and Cohort #2 were implemented in sequential order and separated by a 3-month gap and 13 participants from Cohort #1 also enrolled in Cohort #2. In
pooled analyses, data from these 13 participants in Cohort
#2 (30%) were excluded to ensure that each data point
is independent and to avoid potential bias from training
effects. This yields 63 unique enrolled participants in
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the pooled analysis with 46 (73%) completing the intervention. Reasons reported for attrition included transportation limitations, work schedules, return to cancer
treatment, and post-treatment reconstructive surgery.
Participation in exercise training was recorded inperson at each exercise session and used to calculate a
cumulative percent participation in training. For stratiﬁed analysis, participation was deﬁned as £50% of sessions attended, 51–74% attended, and ‡75% attended.
Participants self-reported clinical diagnosis of chronic
conditions, which was combined to deﬁne comorbidity
as presence of 0, 1, 2, or >2 chronic conditions. BMI
was divided into normal weight (18.35–24.9; one participant did not reach standard 18.5 cutpoint), overweight
(25–29.9), and obese (‡30) categories based on the
widely accepted ACSM cutpoints.20
Recovery from cancer treatment is nonlinear, and
the survivorship experience is unique to each individual.21 The survivorship experience has been best articulated as a series of seasons in which a cancer patient
moves from an acute stage of diagnosis and treatment
initiation, through an extended stage of treatment cessation and navigating treatment-related side effects,
and into a permanent stage of lower risk of recurrence
but possibly with continued need to manage treatmentrelated side effects.22
The transition from the acute stage to the extended
stage is arguably the most difﬁcult as the specialized
medical and psychosocial care provided during treatment is withdrawn at treatment cessation.23 Survival
statistics are typically based on the number of cancer
patients that survive from diagnosis to 5- and 10-year
marks. These cutpoints, however, do not reﬂect trajectory of improvement of HRQoL, which is the hallmark
of the extended stage of the survivorship experience.24
Furthermore, physiological stress and inﬂammation
(CRP, cortisol) can be greatly affected within months
of treatment cessation.25 Therefore, for this study, time
since treatment (TST) was categorized into three groups
(<1, 1–4, 5+ years) to more ﬁnely stratify the extended
stage based on reports of persistence of treatmentrelated effects from 6 to 12 months after treatment cessation and given the conventional use of 5 years as the
transition from the extended to the permanent stage.
All statistical analyses were conducted using SPSS version 23 (IBM Corp., Armonk, NY). Statistical outliers
were ﬁrst determined by SPSS and removed from the
data analysis. Results with and without outliers were
manually compared using box and normality plots and
to identify major deviations in ﬁndings and to ensure
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Table 1. Power Analysis (a = 0.05)
Variables

Statistical test

Baseline fatigue, TST
Physical activity, baseline fatigue
TT, baseline fatigue
Baseline WC, baseline fatigue
Baseline cortisol, baseline fatigue
Baseline CRP, baseline fatigue
Baseline fatigue, postintervention fatigue
Participation, postintervention fatigue
TST, baseline general health
TST, baseline bodily pain
Baseline CRP, TST
BMI, baseline CRP
Baseline WC, baseline CRP
Postintervention CRP, TST
Baseline cortisol, baseline WC
Baseline cortisol, comorbidity

ANOVA
ANOVA
ANOVA
Unpaired
Unpaired
Unpaired
Unpaired
ANOVA
ANOVA
ANOVA
ANOVA
ANOVA
Unpaired
ANOVA
Unpaired
ANOVA

t-test
t-test
t-test
t-test

t-test
t-test

Effect size

Power

0.323
0.355
0.248
r = 0.832 Cohen’s d = 3.00
r = 0.382 Cohen’s d = 0.828
r = 0.780 Cohen’s d = 2.49
r = 0.844 Cohen’s d = 3.15
0.217
0.468
0.393
0.209
0.541
r = 0.780 Cohen’s d = 2.49
0.084
r = 0.382 Cohen’s d = 0.828
0.114

0.602
0.691
0.491
0.99
0.847
0.99
0.996
0.304
0.591
0.443
1.00
1.00
0.98
0.415
0.553
0.079

ANOVA, analysis of variance; BMI, body mass index; CRP, c-reactive protein; TST, time since treatment; TT, treatment type; WC, waist circumference.

that no more than 10% of data were removed from analysis by SPSS. Sample sizes were ﬁxed on previous participant pools for cohort 1, 2, and pooled sections. For all
statistical and stratiﬁed analyses, alpha levels were set to
0.05, and power levels were set to 0.80 (Table 1). Either
Cohen’s d or Pearson’s r was determined for effect size
where analysis of variances (ANOVAs), t-tests, and multinomial regressions were signiﬁcant.
Unpaired t-tests were used to determine differences
between pooled, preintervention PROMIS fatigue scores
and waistline circumference, baseline cortisol, baseline
CRP, and postintervention fatigue scores. Unpaired ttests were also used in pooled comparisons between
waist circumference and baseline CRP and cortisol values.
A paired t-test was used to compare baseline waist circumference with postintervention waist circumference scores.
One-way ANOVA was used to determine differences
between pooled, preintervention PROMIS fatigue
scores and TST, perceived physical activity, number
of comorbidities, participation, and treatment type
categories. Where ANOVAs were signiﬁcant, Tukey’s
honest signiﬁcant difference was used for post hoc
comparisons. Where homogeneity was violated,
Welch’s p was reported and Games–Howell post
hoc comparisons were used.
One-way ANOVAs were used for comparisons
between TST groups, comorbidity and physical component summary (PCS), mental component summary (MCS), and all eight SF-36 domains. One-way
ANOVAs were also used in pooled comparisons between baseline CRP levels with TST, BMI, and waist
circumference groups and postintervention CRP
levels with TST groups. Finally, one-way ANOVAs

were used for baseline cortisol comparisons with
TST, BMI, and comorbidity.
For stratiﬁed analyses, one-way analysis of covariance was used to determine the effect of covariates
(baseline scores) on postintervention measures for fatigue, cortisol, CRP, PCS, MCS, and all eight SF-36 domains while controlling for BMI, comorbidity, TST,
cancer treatment type, and race.
Results
Participants were, on average, college-educated women
in their early-to-mid 60s with at least two diagnosed
chronic conditions in addition to a cancer diagnosis
(Table 2). The majority of participants identiﬁed as
white, and approximately one-third identiﬁed with a historically underrepresented racial minority group. Given
that the majority of participants were women, the most
represented cancer types were breast and gynecologic cancers (Table 2). Before the intervention, 25.4% participants
self-reported their physical activity level as very good or
good, whereas 74.6% of participants reported okay or
needs improvement.
NIH PROMIS fatigue
At baseline, PROMIS fatigue scores were signiﬁcantly
worse for participants completing treatment within
the last year compared to those with a TST greater
than 5 years ( p = 0.038; r = 0.323), suggesting a greater
burden of fatigue among survivors that have more recently completed cancer treatment. Those who perceived their physical activity level as very good had
signiﬁcantly better fatigue scores ( p = 0.039; r = 0.355)
compared to those who reported needs improvement.
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Table 2. Demographics of Participants at Baseline
Variable
Age (mean years – SD)
Sex, male
Sex, female
Race
White
African American, Hispanic
Other/multiracial
Education
High school education
Some college
4-Year college education
Employment status
Employed
Retired
Unemployed
Disabled/other support
Time since treatment (mean years – SD)
Cancer type
Breast
Colorectal
Myeloma/lymphoma
Gynecologic
Thyroid
Prostate
Skin
Lung
Diagnosed chronic conditions (mean – SD)

Cohort #1 (n = 33)

Cohort #2 (n = 43)

p

61 – 12.58
6 (18%)
27 (82%)

65 – 7.39
1 (2%)
42 (98%)

0.080
0.017*

20 (61%)
11 (33%)
2 (6%)

29 (67%)
10 (23%)
4 (10%)

0.585

2 (6%)
10 (30%)
21 (64%)

3 (7%)
14 (33%)
26 (60%)

0.958

9 (27%)
11 (33%)
3 (9%)
10 (31%)
4.30 – 8.26

10 (23%)
21 (49%)
2 (5%)
10 (23%)
6.93 – 3.84

0.552

17 (52%)
7 (21%)
3 (9%)
2 (6%)
2 (6%)
1 (3%)
1 (3%)
0 (0%)
2.34 – 0.74

13 (30%)
2 (5%)
3 (7%)
22 (52%)
1 (2%)
1 (2%)
0 (0%)
1 (2%)
2.37 – 1.64

0.071
<0.001*

0.920

*Statistically signiﬁcant at a = 0.05.
SD, standard deviation.

Comorbid burden was not associated with fatigue
scores, but there was a difference in fatigue scores
between no chemotherapy and chemotherapy treatment
groups ( p = 0.043; r = 0.248). At baseline, a positive relationship was observed with waist circumference and
fatigue ( p < 0.0001; r = 0.832; d = 3.00). Fatigue scores
were also associated with baseline cortisol ( p < 0.0001;
r = 0.382; d = 0.828) and CRP levels ( p < 0.0001; r =
0.780; d = 2.49).
After 26 weeks of exercise intervention, self-reported
NIH PROMIS fatigue scores for the pooled cohort improved by a noteworthy two points ( p = 0.092). There appears to be a dose–response relationship between percent
of sessions attended during the intervention and improvement in self-reported fatigue scores (Fig. 1), although results lost signiﬁcance at an alpha of 0.05 when controlling
for baseline scores ( p = 0.178). In stratiﬁed analysis, baseline BMI, comorbidity, TST, cancer treatment type, and
race had no observable modifying effect on the relationship between participation and fatigue.
SF-36 HRQoL survey
Among Cohort #2 participants, baseline TST was inversely related to baseline physical function ( p = 0.068)

and baseline general health ( p = 0.007; r = 0.468), suggesting that those with longer TST had worsened physical function and general health. TST was positively
associated with bodily pain ( p = 0.026; r = 0.393), suggesting greater self-reported pain in those furthest from
treatment cessation. No observable TST relationship
was detected for physical role, vitality, social function,
emotional role, mental health, PCS, and MCS. Comorbid
burden was inversely related to vitality ( p = 0.019) and
physical function ( p = 0.0827). However, no associations
were identiﬁed for comorbid burden and physical role,
bodily pain, general health, social function, emotional
role, mental health, or MCS.
Participants in Cohort #2 that reported a higher
comorbid burden at baseline appeared to experience
the greatest improvements in the SF-36 vitality domain
after 26 weeks of CART ( p = 0.019). Signiﬁcant pre- to
postintervention improvements in self-reported bodily
pain ( p = 0.006) and limitations in social functioning
( p = 0.034) were also observed (Table 3). No signiﬁcant
postintervention changes were identiﬁed for the remaining ﬁve SF-36 domains (Table 3).
Postintervention changes in bodily pain appeared to
be mediated by TST ( p = 0.013), but not modiﬁed by
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FIG. 1. Effect of participation frequency on NIH PROMIS fatigue domain scores after 26 weeks of group
exercise, The IMPAACT Study 2014–2016, n = 49. IMPAACT, Improving Physical Activity After Cancer
Treatment; NIH PROMIS, National Institutes of Health’s Patient Reported Outcomes Measurement
Information System.

baseline BMI, comorbid burden, cancer treatment type,
and race. The observed postintervention change in social functioning was not modiﬁed by TST. Improvements in all SF-36 domains appeared to be related to
frequency of participation in the intervention in a
dose–response manner; however, none of the dose–response relationships were signiﬁcant at an alpha of 0.05
(Fig. 2). Postintervention SF-36 domain scores from
Cohort #1 were not different than those from Cohort
#2 (Table 4). The mental health and physical health
summary scores (MCS and PCS, respectively) did not

differ signiﬁcantly between cohorts after the 26-week
intervention (Table 5).
C-reactive protein
At baseline, mean CRP levels were lower in the <1 year
TST group compared to the 1–4 year (Welch’s p = 0.0250)
and 5+ year (Welch’s p = 0.009) TST groups (Table 6). A
positive relationship was observed between waist circumference and CRP ( p < 0.0001; r = 0.780; d = 2.49) and between BMI and CRP (Welch’s p < 0.0001; r = 0.541) at
baseline. However, the relationship between baseline

Table 3. SF-36 Subscale and Summary Score Assessments: Preintervention to Postintervention (n = 35)
Subscale measure
Vitality
Bodily pain
Mental health
Physical functioning
Social functioning
Emotional roles
Physical roles
General health
PCS
MCS

Cohort #2 preintervention
mean (SD)
51.15
50.54
52.96
48.73
50.60
50.59
47.46
52.88
48.73
52.63

Cohort #2 postintervention
mean (SD)

(10.81)
(9.51)
(7.66)
(7.64)
(9.17)
(6.81)
(10.84)
(9.91)
(10.14)
(8.07)

*Statistically signiﬁcant at a = 0.05.
MCS, mental component summary; PCS, physical component summary.

51.40
48.20
52.40
47.03
47.75
49.50
46.69
54.29
48.04
51.82

(10.40)
(10.07)
(9.91)
(8.75)
(11.66)
(10.05)
(10.51)
(9.98)
(9.18)
(10.25)

Pre–post mean change
mean (SD)

p

0.25 (0.41)
2.34 (0.56)
0.56 (2.25)
1.70 (1.11)
2.85 (2.49)
1.09 (3.24)
0.77 (0.33)
1.41 (0.07)
0.69 (0.96)
0.81 (2.18)

0.890
0.006*
0.546
0.077
0.034*
0.441
0.659
0.156
0.457
0.466
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FIG. 2. Effect of participation frequency on SF-36 domains after 26 weeks of group exercise, The IMPAACT
Study 2015–2016 (Cohort #2), n = 35.

waist circumference and CRP lost signiﬁcance after
controlling for TST ( p = 0.815).
Collectively, this cross-sectional analysis suggests a
synergism among the CRP, TST, and waist circumference variables among cancer survivors that differ from
the expected linear CRP and waist circumference (central adiposity) relationship observed in cancer-free
adults. There was no observable relationship between
age and CRP levels or between comorbid burden and
CRP levels at baseline.
Following the 26-week intervention, waist circumference decreased on average by 3.40 cm ( p = 0.0002).
A mean decrease of 1.64 – 10.11 mg/L in CRP levels
was also observed in the combined cohort (Fig. 3). Participants who were within 1 year of treatment completion experienced greater improvements in post CRP

levels compared to those who had treatment from 1
to 4 years (Welch’s p = 0.030) and 5 or more years
ago (Welch’s p = 0.023). The dose–response relationship between participation and decreases in CRP was
not mediated by treatment type.
Cortisol
In the pooled analysis, baseline cortisol levels were not
associated with TST nor found to be signiﬁcantly different than postintervention cortisol levels (Table 6). No association was detected between baseline cortisol and BMI
category, but a positive correlation was observed with
waist circumference ( p < 0.0001; r = 0.382; d = 0.828),
suggesting a role for central adiposity. A positive association was observed between comorbid burden and baseline cortisol levels ( p < 0.0001; r = 0.114), indicating that

Table 4. SF-36 Subscale and Summary Score Assessments: Cohort Comparison
Subscale measure
Vitality
Bodily pain
Mental health
Physical functioning
Social functioning
Emotional roles
Physical roles
General health

Cohort #1 (n = 15)
postintervention mean (SD)
50.22
48.88
51.04
48.13
47.65
49.44
48.47
53.91

(11.0)
(8.51)
(8.53)
(9.38)
(9.17)
(7.49)
(9.05)
(9.33)

Cohort #2 (n = 35)
postintervention mean (SD)
51.40
48.20
52.40
47.03
47.75
49.50
46.69
54.29

(10.40)
(10.07)
(9.91)
(8.75)
(11.66)
(10.05)
(10.51)
(9.98)

Post mean differences
between cohorts
1.18
0.68
1.36
1.10
0.10
0.06
1.78
0.38

(0.6)
(1.56)
(1.38)
(0.63)
(2.49)
(2.56)
(1.46)
(0.65)

p
0.719
0.820
0.645
0.691
0.976
0.983
0.570
0.900
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with multiple chronic conditions experienced the most
noteworthy postintervention improvement in bodily
pain, social functioning, and vitality.
Self-reported NIH PROMIS fatigue scores improved
marginally with increased participation in the 26-week
intervention by a noteworthy two points. Participants
also improved self-reported bodily pain and limitations
in social functioning following 26 weeks of CART.
These ﬁndings support previous studies in the adult
breast cancer survivor population that found improvements in SF-36 domains following a resistance training
program,27 an aerobic exercise program,18 or an exercise education program.17

Table 5. SF-36 Subscale and Summary Score Assessments:
Summary Score Comparison
Postintervention

PCS score
mean (SD)

MCS score
mean (SD)

p

Cohort #1 (n = 15)
Cohort #2 (n = 35)

49.19 (9.32)
48.04 (9.18)

50.35 (9.58)
51.82 (10.25)

0.739
0.114

participants with multiple comorbidities were more likely
to experience high cortisol levels.
Discussion
Summary of ﬁndings
At baseline, 75% of this study’s participants reported an
average or below average perception of their physical
activity levels. In addition, participants with poorer
perceptions of their physical activity levels were more
likely to have completed treatment recently. This ﬁnding is consistent with Gjerset et al. who found that
among cancer survivors experiencing chronic fatigue,
86% desired physical training compared to 65% of survivors without chronic fatigue.26
Self-reported fatigue was particularly noteworthy
among participants who received chemotherapy and
positively associated with increased baseline body
weight and cortisol levels. It was also noted that participants with higher self-reported comorbidity had
higher cortisol levels and decreased vitality and physical function, observations consistent with poorer quality of life due to multiple medical conditions and the
stress of navigating poorer health. However, participants

The role of social support
The peer afﬁrmation and social support received during this group exercise intervention may have positively inﬂuenced the perception of their health and
physical ability. Social support could provide a beneﬁcial effect due to continued positive experiences and socially rewarded actions in the exercise intervention.
Support from a social network is related to positive
physical health outcomes through neuroendocrine
changes.28
This social support may have also contributed to
the high program adherence demonstrated throughout the intervention. Fraser and Spink showed high
exercise intervention compliance in adult females
that valued the role of social support.29 Likewise,
Nock et al. interviewed breast cancer survivors following a group exercise program and found that social

Table 6. Mean Values of Pre- and Postoutcome Variables and Mean Values of Pre- and Postoutcome Variables
by Time Since Treatment Group
Pre (0 weeks)
Outcome variable

TST group

CRP (mg/L)

—
<1 year
1–4 years
5+ years

21.45
7.27
25.27
23.02

(22.82)
(4.50)
(26.76)
(24.04)

—
0.025a,*
0.955b
0.009c,*

28.97
4.73
34.91
25.32

(39.13)
(3.84)
(40.08)
(33.70)

0.210
0.030a,*
0.726b
0.023c,*

Cortisol (ng/mL)

—
<1 year
1–4 years
5+ years

162.17
193.15
143.01
166.56

(89.44)
(91.62)
(66.72)
(106.20)

—
0.317a
0.663b
0.699c

173.00
150.10
62.11
163.33

(101.60)
(42.42)
(16.03)
(76.45)

0.556
0.978a
0.987b
0.950c

Waist circumference (cm)

—
<1 year
1–4 years
5+ years

94.94
99.30
97.01
94.47

(17.61)
(14.19)
(20.03)
(17.98)

—
0.931a
0.896b
0.715c

91.54
90.70
91.73
90.68

(15.26)
(15.44)
(16.67)
(15.33)

0.0002**
0.991a
1.000b
0.977c

a

Mean (SD)

Post (26 weeks)

Post hoc comparison between <1 and 1–4 year groups.
Post hoc comparison between 1–4 and 5+ year groups.
Post hoc comparison difference between <1 and 5+ year groups.
*Signiﬁcant difference between post hoc comparison ( p < 0.05).
**Signiﬁcant difference between pre- and postoutcome variable ( p < 0.05).

b
c

p

Mean (SD)

p
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FIG. 3. Effect of CART participation frequency on CRP and cortisol biomarkers after 26 weeks of group
exercise, The IMPAACT Study 2014–2016, n = 46. CART, combined aerobic and resistance training; CRP,
c-reactive protein.

support was one of three primary motivators to engage in the program.30
Mediators of stress-related biomarkers
In addition to examining the potential for improving
HRQoL and perceived barriers with exercise among
cancer survivors, this study also contributes new insight into how the anti-inﬂammatory effects of exercise
and reduction of CRP may be mediated by body composition and TST.5 The intervention appeared to have
the greatest impact on reducing CRP levels among participants that had most recently completed treatment,
which underscores the greater opportunity for improvement with earlier intervention post-treatment.
CRP levels also responded positively to exercise intervention among those participants with normal baseline
levels of CRP, which is consistent with previously published studies.31,32
Exercise did not appear to have a substantial effect
on CRP among those cancer survivors with above normal baseline levels of CRP. The abnormal CRP levels
(>3.0 mg/L) are indicative of chronic inﬂammation
and might be related to a participant’s treatment regimen, body weight, or a combination of both.33 This
suggests a need to further examine CRP levels speciﬁcally in cancer survivors to establish a separate scale

for average CRP level by body weight, TST, treatment
type, and cancer type.
Currently, levels above 10 mg/mL are considered indicative of acute inﬂammation, and levels above 25 mg/
mL are excluded from analysis as too extreme.34 However, this exclusionary approach may not be ideal for a
population of cancer survivors and may limit the full
elucidation of the CRP response pathway. In addition,
before the intervention cortisol levels were positively associated with waist circumference. Thus, more attention
to the inﬂuence of body composition on stress-related
inﬂammation is needed given that the body composition
of most adults, especially postmenopausal women, shifts
toward increases in visceral fat mass with aging.
Given that previously published studies of different
exercise modalities report a mixture of outcomes regarding CRP and inﬂammatory mediators,35 it is possible
that survivors with unique biomarker proﬁles may
need more speciﬁc exercise prescriptions for aerobic
and resistance training.
Conclusions
This study had multiple strengths, including above average study compliance rates, completion of both perceived and physiological measures of fatigue and stress,
and inclusion of covariates, including comorbid burden
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and TST in analysis. The length of this intervention was
longer than the majority of previous cancer survivorship
studies and included a novel group exercise design.
Acceptability to the intervention is demonstrated by
an average participation of 73% for the pooled cohort,
despite complications that would be expected for an
older and medically complex population. The difference in participation between the two cohorts might
be explained by times that sessions were offered.
Cohort #1 participants were given the option of participating in either a noon or 5pm session. Cohort #2 participants were given the option of participating in
either a 10am or a noon session, and since Cohort #2
had more retired individuals, this may have helped
with attrition.
Despite the encouraging results demonstrated in the
study, there are limitations that must be considered.
First, results may not be generalizable to other cancer
populations given the small sample size and narrow
range of cancer types included in this study. A control
group may have strengthened our ﬁndings, however,
the primary aim was to determine if there was a dosedependent response between participation and change
in outcome measures. This allowed comparison between
frequently attending and low attending participants as
an internal control/stratum.
In conclusion, this study suggests that starting an exercise program would be of greatest beneﬁt to those patients who have most recently completed treatment and
who have received chemotherapy in particular. The
ﬁndings from this study suggest a complex relationship
between treatment, body weight, fatigue, and biomarkers of stress and inﬂammation. The intricate mapping
of the relationships between stress-related inﬂammation, exercise interventions, and perceived HRQoL
among cancer survivors is still being developed, and
larger studies will be needed to establish the temporality and directionality of these relationships.
Acknowledgments
The authors sincerely thank the participants of the Loyola Marymount University IMPAACT Study and their
research collaborators, Hawley Almstedt, Silvie Grote,
Stephanie Perez, Todd Shoepe, and Sarah Strand. The
authors are grateful to Danielle Good-Dawson and
Rakiyah Johnson for their consistent administrative
and laboratory support of the IMPAACT Study. The
authors also thank the following divisions and programs at Loyola Marymount University for their support of student research assistants: Frank R. Seaver

61

College of Science and Engineering, the McNair Scholars Program, the Rains Research Assistant Program,
and the Summer Undergraduate Research Program.
This study was funded by the Tower Cancer Research
Foundation’s Community Partner Grant (award period:
1/1/15–12/31/15) and by an award granted by the Charitable Division of the QueensCare Foundation (award
period: 1/1/15–12/31/15). Multiplex assays were performed in the USC Immune Monitoring Core Facility
that is supported, in part, by the National Cancer Institute Cancer Center Shared Grant award P30CA014089.
The content is solely the responsibility of the authors
and does not necessarily represent the ofﬁcial views of
the National Cancer Institute or the National Institutes
of Health.
Author Disclosure Statement
Tarleton received funding to cover the cost of research
supplies and exercise equipment from the Tower Cancer
Research Foundation (Community Partner Grant) and
from the QueensCare Foundation (Charitable Division).
These funding sources did not provide salary support
for the principal investigator and other key personnel.
Ricci, Flores, Kuroyama, and Asher declare that they
have no conﬂicts of interest.
References
1. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the ‘‘Silver Tsunami’’: prevalence trajectories and comorbidity burden among older
cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev.
2016;25:1029–1036.
2. Reyes-Gibby CC, Anderson KO, Morrow PK, et al. Depressive symptoms
and health-related quality of life in breast cancer survivors. J Womens
Health (Larchmt). 2012;21:311–318.
3. Carmack CL, Basen-Engquist K, Gritz ER. Survivors at higher risk for adverse late outcomes due to psychosocial and behavioral risk factors.
Cancer Epidemiol Biomarkers Prev. 2011;20:2068–2077.
4. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related
fatigue in adults. Cochrane Database Syst Rev. 2012;11:CD006145.
5. Gleeson M, Bishop NC, Stensel DJ, et al. The anti-inﬂammatory effects
of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11:607–615.
6. Short CE, James EL, Plotnikoff RC. How social cognitive theory can help
oncology-based health professionals promote physical activity among
breast cancer survivors. Eur J Oncol Nurs. 2013;17:482–489.
7. Meneses-Echavez JF, Correa-Bautista JE, Gonzalez-Jimenez E, et al. The
effect of exercise training on mediators of inﬂammation in breast cancer
survivors: a systematic review with meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016;25:1009–1017.
8. Kamath J. Cancer-related fatigue, inﬂammation and thyrotropin-releasing
hormone. Curr Aging Sci. 2012;5:195–202.
9. Imayama I, Alfano CM, Neuhouser ML, et al. Weight, inﬂammation,
cancer-related symptoms and health related quality of life among breast
cancer survivors. Breast Cancer Res Treat. 2013;140:159–176.
10. Xiao C, Miller AH, Felger J, et al. Depressive symptoms and inﬂammation
are independent risk factors of fatigue in breast cancer survivors.
Psychol Med. 2017;47:1733–1743.
11. Jensen RE, Potosky AL, Reeve BB, et al. Validation of the PROMIS physical
function measures in a diverse US population-based cohort of cancer
patients. Qual Life Res. 2015;24:2333–2344.

Ricci, et al.; BioResearch Open Access 2018, 7.1
http://online.liebertpub.com/doi/10.1089/biores.2018.0003

12. Jensen RE, Potosky AL, Moinpour CM, et al. United States populationbased estimates of patient-reported outcomes measurement information
system symptom and functional status reference values for individuals
with cancer. J Clin Oncol. 2017;35:1913–1920.
13. Leung YW, Brown C, Cosio AP, et al. Feasibility and diagnostic accuracy of
the Patient-Reported Outcomes Measurement Information System
(PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care. Cancer. 2016;122:2906–2917.
14. Yost KJ, Eton DT, Garcia SF, et al. Minimally important differences were
estimated for six Patient-Reported Outcomes Measurement Information
System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507–516.
15. Bjorner JB, Rose M, Gandek B, et al. Difference in method of administration did not signiﬁcantly impact item response: an IRT-based analysis
from the Patient-Reported Outcomes Measurement Information System
(PROMIS) initiative. Qual Life Res. 2014;23:217–227.
16. McHorney CA, Ware JE, Lu JF, et al. The MOS 36-item Short-Form Health
Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40–66.
17. Dolan LB, Barry D, Petrella T, et al. The cardiac rehabilitation model improves ﬁtness, quality of life, and depression in breast cancer survivors.
J Cardiopulm Rehabil Prev. 2017; [Epub ahead of print]; DOI: 10.1097/
HCR.0000000000000256.
18. Di Blasio A, Morano T, Cianchetti E, et al. Psychophysical health status of
breast cancer survivors and effects of 12 weeks of aerobic training.
Complement Ther Clin Pract. 2017;27:19–26.
19. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports
Medicine roundtable on exercise guidelines for cancer survivors. Med
Sci Sports Exerc. 2010;42:1409–1426.
20. Pescatello L. (ed.) ACSMs Guidelines for Exercise Testing and Prescription.
Wolters Kluwer/Lippincott Williams & Wilkins Health: Philadelphia, 2014.
21. Boyle DA. Survivorship. Clin J Oncol Nurs. 2006;10:407–421.
22. Mullan F. Seasons of survival: reﬂections of a physician with cancer. N
Engl J Med. 1985;313:270–273.
23. Prevention CfDCa. A National Action Plan for Cancer Survivorship: advancing Public Health Strategies. 2004; https://www.cdc.gov/cancer/
survivorship/pdf/plan.pdf. (Last accessed May 30, 2017).
24. Leigh SA, Williams JE, Stoval E. Survivorship: from the moment of
diagnosis. Cancer 1998;83:1710–1713.
25. Bower JE, Ganz PA, Irwin MR, et al. Inﬂammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep
disturbance share a common underlying mechanism? J Clin Oncol. 2011;
29:3517–3522.
26. Gjerset GM, Loge JH, Kiserud CE, et al. Perceived needs for different
components in a rehabilitation program among cancer survivors with
chronic fatigue compared to survivors without chronic fatigue. Acta
Oncol. 2017;56:245–253.
27. Serra MC, Ryan AS, Ortmeyer HK, et al. Resistance training reduces inﬂammation and fatigue and improves physical function in older breast
cancer survivors. Menopause. 2018;25:211–216.
28. Uchino BN, Bowen K, Carlisle M, et al. Psychological pathways linking
social support to health outcomes: a visit with the ‘‘ghosts’’ of research
past, present, and future. Soc Sci Med. 2012;74:949–957.
29. Fraser SN, Spink KS. Examining the role of social support and group cohesion in exercise compliance. J Behav Med. 2002;25:233–249.
30. Nock NL, Owusu C, Flocke S, et al. A community-based exercise and
support group program improves quality of life in African-American

62

31.

32.

33.

34.

35.

breast cancer survivors: a quantitative and qualitative analysis. Int J Sports
Exerc Med. 2015;1:pii: 020.
Colbert LH, Visser M, Simonsick EM, et al. Physical activity, exercise,
and inﬂammatory markers in older adults: ﬁndings from the Health,
Aging and Body Composition Study. J Am Geriatr Soc. 2004;52:1098–
1104.
Kohut ML, McCann DA, Russell DW, et al. Aerobic exercise, but not ﬂexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent
of beta-blockers, BMI, and psychosocial factors in older adults. Brain
Behav Immun. 2006;20:201–209.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New
Engl J Med. 2008;359:2195–2207.
van Gemert WA, May AM, Schuit AJ, et al. Effect of weight loss with or
without exercise on inﬂammatory markers and adipokines in postmenopausal women: the SHAPE-2 trial, a randomized controlled trial. Cancer
Epidemiol Biomarkers Prev. 2016;25:799–806.
Jones SB, Thomas GA, Hesselsweet SD, et al. Effect of exercise on markers
of inﬂammation in breast cancer survivors: the Yale exercise and survivorship study. Cancer Prev Res (Phila). 2013;6:109–118.

Cite this article as: Ricci JM, Flores V, Kuroyama I, Asher A, Tarleton
HP (2018) Pilot study of dose-response effects of exercise on change
in c-reactive protein, cortisol, and health-related quality of life among
cancer survivors, BioResearch Open Access 7:1, 52–62, DOI: 10.1089/
biores.2018.0003.

Abbreviations Used
ACSM
ANOVA
BMI
CART
CAT
CRP
HRQoL
IMPAACT

¼
¼
¼
¼
¼
¼
¼
¼

MCS ¼
NIH PROMIS ¼

PCS ¼
SD ¼
TST ¼

American College of Sports Medicine
analysis of variance
body mass index
combined aerobic and resistance training
computerized adaptive testing
c-reactive protein
health-related quality of life
Improving Physical Activity After Cancer
Treatment
mental component summary
National Institutes of Health’s Patient
Reported Outcomes Measurement
Information System
physical component summary
standard deviation
time since treatment

Publish in BioResearch Open Access
Broad coverage of biomedical research
Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing
-

-

liebertpub.com/biores

